Associated Papers
Small Molecule B-RAF Inhibitors as Anti-Cancer Therapeutics: Advances in Discovery, Development, and Mechanistic Insights.
Anaya YA et al.
International Journal of Molecular Sciences, 2025
Real-World Evidence of the Prevalence of Driver Mutations in Anorectal Melanoma.
Jutten E et al.
Molecular Diagnosis & Therapy, 2025
Tumor DNA from tumor in situ fluid was used to track evolution of glioma under first-line treatment.
Yu J et al.
Frontiers in Oncology, 2025
41179686 (PubMed )
Supplement: Table3.xls › Mutations_in_after_120d_TISF
Landscape and prognostic significance of oncogene drivers in metastatic castration sensitive prostate cancer.
Wang T et al.
Translational Cancer Research, 2024
Baseline mutational profiles of patients with carcinoma of unknown primary origin enrolled in the CUPISCO study.
Westphalen CB et al.
Esmo Open, 2023
37922692 (PubMed )
Supplement: mmc1.docx
Clinicopathological Features of Non-Small Cell Lung Carcinoma with BRAF Mutation.
Ambrosini-Spaltro A et al.
Current Oncology (toronto, Ont.), 2023
BRAF and MEK Targeted Therapies in Pediatric Central Nervous System Tumors.
Talloa D et al.
Cancers, 2022
Select a paper to view details